The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.

The present disclosure provides chimeric adenoviral vectors comprising a nucleic acid encoding a coronavirus disease 2019 (COVID-19) protein and an adjuvant and methods for using the vectors to elicit an immune response to the SARS-CoV-2 protein in order to treat COVID-19.

The present invention relates to the construction and application of a fusion protein vaccine platform. The present invention provides a vaccine, comprising a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope. The present invention also relates to use of a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope in the preparation of prophylactic or therapeutic compositions. The vaccine of the present invention can be produced by eukaryotic cell expression systems to prepare wild-type and various mutant antigen vaccines, and vaccination by means of subcutaneous/muscular or nasal or other routes can lead to a strong immune response to a body. The vaccine of the present invention can be used as a prophylactic or therapeutic vaccine.

The present invention relates to a virus-like particle for preventing or treating toxoplasmosis, comprising influenza virus matrix protein 1; and surface antigen proteins comprising an inner membrane complex, Rhoptry protein 18 and Microneme protein 8 derived from Toxoplasma gondii, and a pharmaceutical composition comprising the same.

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.

Described is a vaccine composition comprising an effective amount of at least one polypeptide selected from the group of IdeSsuis, rIdeSsuis, an analogue or a fragment thereof, or a polynucleotide encoding the same. This vaccine composition is used in the prophylactic, metaphylactic or therapeutic treatment of a Streptococcus suis infections in pigs or humans.

Provided are compositions and methods for vaccinating against picornaviruses. The compositions include modified Newcastle Disease viruses (NDVs) that are sufficient to produce virus-like particles (VLPs) in a host recipient. The modified NDVs contain a single stranded negative sense RNA polynucleotide having nucleotide sequences configured in a 3′-5′ direction encoding sequentially NDV nucleocapsid protein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN) and RNA-dependent RNA polymerase (L) protein. A first nucleotide sequence encoding a picornavirus capsid polyprotein precursor is positioned between the between P and M nucleotide sequences. A second nucleotide sequence encoding a picornavirus protease that is capable of processing the capsid polyprotein precursor is positioned between the HN and L nucleotide sequences. Purified, infectious non-pathogenic NDV particles are included, as are methods for using such particles for vaccination against any infectious picornavirus. Kits and articles of manufacture containing and/or for making the NDV particles are also provided.

The invention relates generally to the field of influenza vaccination, specifically to a two-component vaccine comprising influenza virus strains with native hemagglutinin (HA) and lacking the functional NS gene (delNSI influenza), for use in the vaccination of a subject, wherein a priming composition, comprising one, two or three delNSI influenza virus strains selected from group 1 influenza A virus, group 2 influenza A virus, or group 3, consisting of influenza B virus, is formulated for prime-administration prior to a boosting composition, comprising one, two or three delNSI influenza virus strains of the same group as in the priming composition but differing antigenically in the HA head, formulated for boost-administration. Further, a kit comprising said two-components and its use for preventing influenza virus infection is provided.

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.